

## 1 **S2 Text. Analysis of luciferase cassette in MPXV/Luc+**

### 2 **Introduction**

3 During the experimental infection trial RS14, the sentinel animal, began to show clinical signs  
4 consistent with monkeypox infection, including lethargy, nasal discharge, and pustular lesions on  
5 the tongue. Increased luminescence was not detected in this animal at any time point.

6 Histopathological analysis of these lesions was similar to experimentally infected animals and  
7 several tissues and swabs were positive by real time PCR (tongue, liver, oral swabs, and blood).

### 8 **Materials and Methods**

9 To evaluate the cause of the lack of luciferase expression by the MPXV that infected the sentinel  
10 animal, we isolated virus from tongue and liver, which were highly positive for MPXV real time  
11 PCR. Luciferase expression of these viruses was measured using a plate luminometer. Vero cells  
12 were cultured on 96-well plates. Cells were infected with four ten-fold dilutions of tissue slurry  
13 in DMEM. 100 PFU of MPXV/Congo/Luc+ was used as a positive control. At 24 and 48 hours  
14 post-infection, luciferase expression was detected using the SteadyLite Plus<sup>TM</sup> luciferase  
15 detection kit (PerkinElmer, Waltham, MA) with the VICTOR Light 1420 plate luminometer  
16 (PerkinElmer, Waltham, MA). A duplicate plate was made above was made and fixed at 48  
17 hours post-infection with 1% crystal violet in 10% formalin.

18 To evaluate the potential loss of the luciferase cassette by mutation or presence of a different  
19 strain MPXV, we performed PCR using 10 sets of primers (Table A) that cover the cassette and  
20 flanking regions, and well as genes that differ among MPXV strains. Samples and controls  
21 included the infection study inoculum, MPXV Congo/Luc+ stock, wildtype MPXV (ROC 2003-  
22 358), and a primary lesion from RS15, which was expressing luciferase, tongue, liver, and blood

23 from RS14, and an oral swab from RS14 on day 19 post-infection. All DNA samples were  
 24 extracted using Zymo® g-DNA kit (Zymo Research, Irvine, CA). Quickload Taq 2X Master  
 25 mix or Phusion High fidelity DNA polymerase (New England BioLabs, Ipswich, MA) ,  
 26 following the manufacturer’s suggested protocol on a Geneamp PCR system 9700 (Applied  
 27 Biosystems, Foster City, CA) . Some PCR products were cleaned using Zymo PCR purification  
 28 kit (Zymo Research, Irvine, CA) and sequenced using Sanger sequencing at the University of  
 29 Wisconsin Biotechnology Center (Madison, WI).

30 Finally, to estimate the concentration of wildtype versus recombinant virus, we performed real  
 31 time PCR (as described in Materials and Methods, Quantitative Real Time PCR) to amplify a  
 32 150 bp fragment of the luciferase gene (PCR 10) and two fragments (PCR 11 and 12) that are  
 33 present only in wildtype, non-recombinant virus surrounding the recombination site (S2 Table  
 34 A). Using wildtype virus (MPXV/Congo) DNA, a standard curve was created for PCRs 11 and  
 35 12. DNA from another luciferase-containing virus, which was previously confirmed to only  
 36 contain wildtype virus [20], was used to create a standard curve for PCR 10.

PCR	Genes Amplified	Product Size	Forward Primer	Reverse Primer
PCR 1	Luc+ cassette fragment	312	GAGCACGGAAAGACGATGAC	CCAATCTCCGGTCGCTAA
PCR 2	Luc+ cassette fragment	500	GAGCACGGAAAGACGATGAC	TCGTTATTGATGACCTGGTGG
PCR 3	176-177 intergenic region	2575/5154	ATGGCACGATTGTCAATACTT	CTCGTCGTAATTGGGTTCCTC
PCR 4	left and right flanks	500/2851	CAGGGCCGGCCGGACCGGACT TACATAAATATCTGGG	GCGCCAGGCGCGCCGTTAAAA TACATTCTAATACGG
PCR 5	complement	298	TAAGTACATATGCCATTTTTT GCTTTCTGTATCC	AAGATCGGCCGCACTGCCATT GTTTTTGAGC

PCR 6	CCXR	759	TCAGACACATGCTTTGAGTTTTG	TAGAAACAATATATTGTCCTGGCA
PCR 7	envelope	1045	ATGATGACACCAGAAAACGACG	TCTTTTAACGCATAGTACAGATTGA
PCR 8	qPCR	150	GAGCACGGAAAGACGATGAC	CTTGCTCCACAAACACAACCTCC
PCR 9	qPCR	150	TAATCGTATTTGCGCGATGG	GACGAAGATTGGCCTCAACC
PCR 10	qPCR	150	ACAGCTGTAAATACAGCGGC	CCCAAGTAATGCATTAGGTAAGT


37

38 **Table A.** Primer sequences for PCRs used to determine why RS14, the sentinel rope squirrel,  
39 was infected with Monkeypox virus, but no luminescence was detected. Primer target sequences  
40 within and around the luc+ cassette from RS14, RS15 (an animal infected with a luminescent  
41 MPXV), and stocks from both wildtype MPXV/Congo and recombinant, luciferase expressing,  
42 MPXV/Congo/Luc+.

### 43 **Results**

44 Luminescence was not detected in RS14 tongue or liver by plate luminometer 24 or 48 hours  
45 after infection. The fixed plate contained many viral plaques, confirming that virus was present  
46 and replicating in the cells without expression of luciferase. The positive control, MPXV  
47 Congo/Luc+, was luminescent, as expected.

48 The results of PCR 1 and 2, which amplify a 312 and 500 base pair fragment within the  
49 luciferase cassette, showed that RS14 oral swab, liver, and tongue, as well as wildtype  
50 MPXV/Congo, were negative for the cassette, while the MPXV/Congo/Luc+ was positive  
51 (Figure A). Interestingly, PCRs 3 and 4, which include the flanking regions outside of the  
52 recombinant site, show evidence of the presence of both wildtype and recombinant viruses in  
53 both RS15 lesion and MPXV/Congo/Luc+ stock, while RS14 tongue only had the wildtype band  
54 (Figures B-C).



Stock Congo Luc+= DNA from recombinant virus used for infection (MPXV-Congo/Luc+)

Stock Congo wt= DNA from MPXV Congo wild-type

55

56 **Figure A.** PCR1 and PCR2 gel electrophoresis. The gene map above shows that PCR 1 targeted


57 a 312 bp section in the luciferase cassette. Samples from RS14, including oral swab on day 18,

58 tongue, and liver, show that the infecting virus did not contain the luciferase gene, but the control

59 (MPXV/Congo/Luc+ stock) did. Likewise, in PCR 2, the MPXV/Congo/Luc+ stock was positive


60 for a 500 bp section containing portions of the luciferase and GPT genes, while RS14 samples

61 did not.



62

63 **Figure B.** As shown above, PCR 3 amplified the right and left flanking regions of where the  
 64 Luc+ cassette was inserted in recombinant MPXV/Luc+. The amplicon is expected to be longer  
 65 (5154 vs 2575 bp) in the recombinant MPXV with the luciferase/GPT cassette. RS15 and the  
 66 MPXV/Congo/Luc+ stock, which was used to inoculate rope squirrels, was positive for both  
 67 bands, while RS 14 tongue and RS14 oral swab were only positive for the wildtype, shorter  
 68 amplicon.



69

70 **Figure C.** PCR 4 amplifies a portion of the luciferase/GPT cassette from the left flanking region  
 71 to the downstream gene, gene 177. In non-recombinant MPXV, the amplicon is 500 bp, while it  
 72 is expected to be 2851 if the cassette is present. MPXV/Congo/Luc<sup>+</sup> and RS15 skin lesion are  
 73 positive for both bands, while samples from RS14, the sentinel rope squirrel, are only positive  
 74 for the smaller, 500 bp band.

75 To evaluate that the non-recombinant MPXV was the same as the parental strain, and not a  
 76 contaminant from another strain or potentially from a pre-existing infection in the squirrel, we  
 77 performed three additional PCRs. PCR 5 amplified the complement gene, which is not present  
 78 in West African origin MPXV strains. This showed that all RS14 sample viruses and a positive  
 79 control of an MPXV isolate from Republic of Congo (ROC-2003-358) contained the  
 80 complement gene and was central African in origin. The negative control, a West African origin  
 81 strain from the US outbreak (USA-2003-044), did not amplify this gene. PCR 6 and 7 amplified

82 CCXR and the envelope gene, which are variable among central African strains of MPXV. These  
83 PCRs were positive and sequences of the amplicons were 100% identical to the parental MPXV  
84 strain (ROC-2003-358). Finally, the quantitative real time PCRs (PCRs 8, 9, 10) showed that the  
85 stock and the study inoculum contained approximately equal amounts of the wildtype and  
86 recombinant MPXV/Luc+ (1:1.13 recombinant: non-recombinant).

87 **Conclusions.** Analysis of the luciferase cassette in MPXV/Congo/Luc+ indicates that the  
88 inoculum and recombinant MPXV stock contained two populations of viruses, recombinant and  
89 non-recombinant. RS15 lesion also contained both wildtype and recombinant viruses, although  
90 luminescence was detected in the live animal. RS14 liver, tongue and oral swab contained mostly  
91 or entirely wildtype virus, but the blood showed evidence of the circulation of some recombinant  
92 virus. While all animals in this study were inoculated with both wildtype and recombinant  
93 viruses, both viruses are the same strain of MPXV, therefore pathology and virulence  
94 characteristics are expected to be the same, as shown in [29].

95

96

97